A theranostic approach based on radiolabeled antiviral drugs, antibodies and CRISPR-associated proteins for early detection and treatment of SARS-CoV-2 disease

Shiri Lord, Isaac; Abdollahi, Hamid; Atashzar, Mohammad Reza; Rahmim, Arman; Zaidi, Habib

doi:10.1097/MNM.0000000000001269

Scientific article

Comment

English

A theranostic approach based on radiolabeled antiviral drugs, antibodies and CRISPR-associated proteins for early detection and treatment of SARS-CoV-2 disease

ContributorsShiri Lord, Isaac

; Abdollahi, Hamid; Atashzar, Mohammad Reza; Rahmim, Arman; Zaidi, Habib

Published inNuclear Medicine Communications, vol. 41, no. 9, p. 837-840

Publication date2020

Affiliation entities

Centres et instituts / Centre interfacultaire de neurosciences
Faculté de médecine / Section de médecine clinique / Département de radiologie et informatique médicale

Research groups

Imagerie Médicale (TEP et TEMP) (542)

Citation (ISO format)

SHIRI LORD, Isaac et al. A theranostic approach based on radiolabeled antiviral drugs, antibodies and CRISPR-associated proteins for early detection and treatment of SARS-CoV-2 disease. In: Nuclear Medicine Communications, 2020, vol. 41, n° 9, p. 837–840. doi: 10.1097/MNM.0000000000001269

Article (Published version)

OA OTHER

Identifiers

PID : unige:142492
DOI : 10.1097/MNM.0000000000001269
PMID : 32796470

Additional URL for this publicationhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7485524/

Journal ISSN0143-3636

331views

254downloads

Creation08/14/2020 11:02:00 AM

First validation08/14/2020 11:02:00 AM

Update time03/15/2023 10:43:06 PM

Status update03/15/2023 10:43:05 PM

Last indexation10/31/2024 7:52:37 PM

Archive ouverte UNIGE

A theranostic approach based on radiolabeled antiviral drugs, antibodies and CRISPR-associated proteins for early detection and treatment of SARS-CoV-2 disease

Technical informations